Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Biohaven Ltd.

Capitalization 1.54B 1.33B 1.2B 1.15B 2.1B 142B 2.16B 14.12B 5.66B 68.02B 5.8B 5.67B 244B P/E ratio 2026 *
-3.56x
P/E ratio 2027 * -4.07x
Enterprise value 1.67B 1.44B 1.3B 1.24B 2.27B 154B 2.34B 15.3B 6.13B 73.71B 6.28B 6.15B 264B EV / Sales 2026 *
-
EV / Sales 2027 * 51.8x
Free-Float
84.47%
Yield 2026 *
-
Yield 2027 * -
1 day+0.59%
1 week-3.75%
Current month-10.85%
1 month-15.82%
3 months-3.11%
6 months-26.70%
Current year-9.03%
1 week 9.25
Extreme 9.25
12.1
1 month 9.25
Extreme 9.25
12.1
Current year 9.25
Extreme 9.25
14.01
1 year 7.48
Extreme 7.48
31.18
3 years 7.48
Extreme 7.48
62.21
5 years 5.54
Extreme 5.54
62.21
10 years 5.54
Extreme 5.54
62.21
Manager TitleAgeSince
Chief Executive Officer 55 01/05/2022
Director of Finance/CFO 64 27/09/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 55 01/05/2022
Director/Board Member 61 31/12/2019
Director/Board Member 70 27/09/2022
Change 5d. change 1-year change 3-years change Capi.($)
+0.59%-3.75%-62.83%-22.43% 1.54B
-0.44%-4.19%-8.77%-7.02% 44.96B
+1.03%+2.81%+25.85%+41.23% 33.54B
+0.98%-8.44%+16.94%+45.41% 30.24B
-4.27%-1.74%-9.46%-13.35% 29.97B
-0.93%-1.62%+168.50%+376.20% 19.78B
+0.25%+0.54%+74.06%+126.46% 14.73B
-2.46%+0.30%+38.35%+166.08% 13.58B
+0.22%-3.72%+21.86%+0.38% 12.97B
-5.37%+2.17%+22,573.45%+3,414.48% 12.81B
Average -1.04%-0.60%+2,283.80%+412.74% 21.41B
Weighted average by Cap. -0.92%-0.65%+1,377.53%+267.62%

Financials

2026 *2027 *
Net sales - 25.23M 21.67M 19.58M 18.75M 34.25M 2.32B 35.33M 231M 92.36M 1.11B 94.69M 92.68M 3.98B
Net income -416M -357M -323M -309M -564M -38.19B -582M -3.8B -1.52B -18.31B -1.56B -1.53B -65.56B -404M -347M -314M -300M -549M -37.12B -566M -3.69B -1.48B -17.8B -1.52B -1.48B -63.72B
Net Debt 129M 111M 100M 95.93M 175M 11.86B 181M 1.18B 473M 5.68B 484M 474M 20.35B -239M -205M -185M -177M -324M -21.92B -334M -2.18B -873M -10.51B -896M -876M -37.62B
Logo Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Employees
274
Date Price Change Volume
10/03/26 10.27 $ +0.59% 4,159,067
09/03/26 10.21 $ +2.92% 5,987,878
06/03/26 9.920 $ -3.78% 2,221,590
05/03/26 10.31 $ -2.83% 2,334,545
04/03/26 10.61 $ -0.56% 2,150,867
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
10.27USD
Average target price
21.12USD
Spread / Average Target
+105.70%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW